Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

RT-QuIC: a highly promising diagnostic method for neurodegenerative diseases-advantages and limitations

D. Koníčková, D. Hraboš, K. Menšíková, L. Tučková, M. Kaleta, M. Strnad, C. Colosimo, P. Kaňovský

. 2025 ; 16 (-) : 1578252. [pub] 20250527

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25014293

Although it has been more than 200 years since Parkinson's disease was described, we have not established biomarkers for its definitive diagnosis yet. Moreover, there is a similar case for the entire group of α-synucleinopathies, which are all characterized by the pathological accumulation of aggregated α-synuclein (α-Syn) in the brain and other tissues. In different biological materials (blood, cerebrospinal fluid, saliva, or skin), α-Syn exists in various conformations and various aggregated states depending on the surrounding environment. Lewy bodies have been considered a pathognomonic feature of Parkinson's disease for over 100 years, and α-Syn has been known to be a key component of Lewy bodies for over 25 years, making it possible to confirm the diagnosis by post-mortem examination of brain tissue. To overcome these limitations, novel analytical seed amplification assays (SAAs) were introduced, and they quickly became one of the most effective diagnostic tools for antemortem detection of α-synucleinopathies. As they require minimal sample amounts to provide consistent, rapid, and reliable results, SAAs are ideally suited for biomarker determination. This review examines SAA analytical and detection methods, their advantages and strengths, as well as their limitations and shortcomings that need to be addressed to establish a reliable and reproducible protocol. This could serve as a diagnostic methodology worldwide to determine the presence of pathological α-Syn protein at early stages and help develop effective disease-modifying treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25014293
003      
CZ-PrNML
005      
20250905141323.0
007      
ta
008      
250701e20250527sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fneur.2025.1578252 $2 doi
035    __
$a (PubMed)40496124
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Koníčková, D $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia $u Department of Neurology, University Hospital Olomouc, Olomouc, Czechia
245    10
$a RT-QuIC: a highly promising diagnostic method for neurodegenerative diseases-advantages and limitations / $c D. Koníčková, D. Hraboš, K. Menšíková, L. Tučková, M. Kaleta, M. Strnad, C. Colosimo, P. Kaňovský
520    9_
$a Although it has been more than 200 years since Parkinson's disease was described, we have not established biomarkers for its definitive diagnosis yet. Moreover, there is a similar case for the entire group of α-synucleinopathies, which are all characterized by the pathological accumulation of aggregated α-synuclein (α-Syn) in the brain and other tissues. In different biological materials (blood, cerebrospinal fluid, saliva, or skin), α-Syn exists in various conformations and various aggregated states depending on the surrounding environment. Lewy bodies have been considered a pathognomonic feature of Parkinson's disease for over 100 years, and α-Syn has been known to be a key component of Lewy bodies for over 25 years, making it possible to confirm the diagnosis by post-mortem examination of brain tissue. To overcome these limitations, novel analytical seed amplification assays (SAAs) were introduced, and they quickly became one of the most effective diagnostic tools for antemortem detection of α-synucleinopathies. As they require minimal sample amounts to provide consistent, rapid, and reliable results, SAAs are ideally suited for biomarker determination. This review examines SAA analytical and detection methods, their advantages and strengths, as well as their limitations and shortcomings that need to be addressed to establish a reliable and reproducible protocol. This could serve as a diagnostic methodology worldwide to determine the presence of pathological α-Syn protein at early stages and help develop effective disease-modifying treatment.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Hraboš, D $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia $u Department of Neurology, University Hospital Olomouc, Olomouc, Czechia $u Department of Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia $u Olomouc Brain Bank, Department of Neurology and Department of Clinical and Molecular Pathology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Olomouc, Czechia
700    1_
$a Menšíková, K $u Department of Neurology, University Hospital Olomouc, Olomouc, Czechia $u Olomouc Brain Bank, Department of Neurology and Department of Clinical and Molecular Pathology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Olomouc, Czechia
700    1_
$a Tučková, L $u Department of Neurology, University Hospital Olomouc, Olomouc, Czechia $u Department of Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia $u Olomouc Brain Bank, Department of Neurology and Department of Clinical and Molecular Pathology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Olomouc, Czechia
700    1_
$a Kaleta, M $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Olomouc, Czechia
700    1_
$a Strnad, M $u Department of Neurology, University Hospital Olomouc, Olomouc, Czechia $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Olomouc, Czechia
700    1_
$a Colosimo, C $u Department of Neurology, Santa Maria University Hospital, Terni, Italy
700    1_
$a Kaňovský, P $u Department of Neurology, University Hospital Olomouc, Olomouc, Czechia $u Olomouc Brain Bank, Department of Neurology and Department of Clinical and Molecular Pathology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Olomouc, Czechia
773    0_
$w MED00174552 $t Frontiers in neurology $x 1664-2295 $g Roč. 16 (20250527), s. 1578252
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40496124 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250701 $b ABA008
991    __
$a 20250905141310 $b ABA008
999    __
$a ok $b bmc $g 2388035 $s 1251413
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 16 $c - $d 1578252 $e 20250527 $i 1664-2295 $m Frontiers in neurology $n Front Neurol $x MED00174552
LZP    __
$a Pubmed-20250701

Najít záznam

Citační ukazatele

Možnosti archivace